Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 31, 2026, 5:15 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 97–120 of 297 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Fasting First Clear all
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Cilostazol 50 mg Tablets Under Fasting Conditions

NCT00839930
View directory record Official record
Conditions
Healthy
Interventions
Cilostazol 50 mg Tablets, Pletal®
Drug
Lead sponsor
Teva Pharmaceuticals USA
Industry
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2004
U.S. locations
2
States / cities
East Grand Forks, Minnesota • Fargo, North Dakota
Source: ClinicalTrials.gov public record
Updated Aug 20, 2024 · Synced Oct 31, 2026, 5:15 PM EDT
Terminated Phase 2 Interventional Results available

Dabrafenib/Trametinib, BRAF or BRAF AND MEK Pre-op With BRAF and MEK Post-op, Phase IIB, Melanoma With Brain Mets,Biomarkers and Metabolites

NCT01978236
View directory record Official record
Conditions
Melanoma and Brain Metastases
Interventions
Dabrafenib 150 mg, Trametinib 2.0 mg
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
2
States / cities
Pittsburgh, Pennsylvania • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Aug 17, 2018 · Synced Oct 31, 2026, 5:15 PM EDT
Completed Phase 2 Interventional Results available

Cabozantinib (XL-184) Monotherapy for Advanced Cholangiocarcinoma

NCT01954745
View directory record Official record
Conditions
Bile Duct Cancer, Intrahepatic Cholangiocarcinoma, Cholangiocarcinoma of the Extrahepatic Bile Duct
Interventions
Cabozantinib
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
3
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Feb 3, 2017 · Synced Oct 31, 2026, 5:15 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

The Effect of Motor Imagery Dosage on Motor Learning in Healthy Adults

NCT06299345
View directory record Official record
Conditions
Healthy
Interventions
Motor imagery training, NO motor imagery training
Other
Lead sponsor
Ahmed Mahmoud Kadry
Other
Eligibility
18 Years to 35 Years
Enrollment
27 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022
U.S. locations
1
States / cities
Mequon, Wisconsin
Source: ClinicalTrials.gov public record
Updated Mar 12, 2024 · Synced Oct 31, 2026, 5:15 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Mycophenolate Mofetil 250 mg Capsules Under Fasting Conditions

NCT00911274
View directory record Official record
Conditions
Healthy
Interventions
Mycophenolate Mofetil, CellCept®
Drug
Lead sponsor
Teva Pharmaceuticals USA
Industry
Eligibility
18 Years and older
Enrollment
53 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Aug 19, 2024 · Synced Oct 31, 2026, 5:15 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Glimepiride 4 mg Tablets Under Fasting Conditions

NCT00834340
View directory record Official record
Conditions
Healthy
Interventions
Glimepiride 4 mg Tablets, AMARYL® 4 mg Tablets
Drug
Lead sponsor
Teva Pharmaceuticals USA
Industry
Eligibility
18 Years and older
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2003
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Aug 19, 2024 · Synced Oct 31, 2026, 5:15 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Effect of Exendin-(9-39) on Fasting Adaptation and Protein Sensitivity

NCT00897676
View directory record Official record
Conditions
Congenital Hyperinsulinism
Interventions
Exendin-(9-39), placebo
Drug
Lead sponsor
Diva De Leon
Other
Eligibility
6 Months to 18 Years
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2017
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Mar 13, 2020 · Synced Oct 31, 2026, 5:15 PM EDT
Completed Not applicable Interventional

The Effect of Exercise on Strength and Mobility and Corresponding CNS Plasticity in Multiple Sclerosis Patients

NCT01816100
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
specifically design 6 month resistance training program, 6 months weight resistance and balance program
Other · Behavioral
Lead sponsor
University of Nebraska
Other
Eligibility
19 Years to 65 Years
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
1
States / cities
Omaha, Nebraska
Source: ClinicalTrials.gov public record
Updated Sep 1, 2023 · Synced Oct 31, 2026, 5:15 PM EDT
Terminated Phase 2 Interventional Results available

A Study of Orally Administered JBPOS0101 in Refractory Infantile Spasms Patients

NCT03976076
View directory record Official record
Conditions
Refractory Infantile Spasms
Interventions
JBPOS0101
Drug
Lead sponsor
Bio-Pharm Solutions Co., Ltd.
Industry
Eligibility
6 Months to 36 Months
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
17
States / cities
Little Rock, Arkansas • Los Angeles, California • San Francisco, California + 13 more
Source: ClinicalTrials.gov public record
Updated Aug 22, 2024 · Synced Oct 31, 2026, 5:15 PM EDT
Enrolling by invitation Phase 4 Interventional Accepts healthy volunteers

Imaging Biomarkers of Pancreatic Function and Disease

NCT05659147
View directory record Official record
Conditions
Pancreatitis, Diabetes Mellitus
Interventions
Research MRI without administration of intravenous secretin, Research MRI with administration of intravenous secretin, Genetic Sequencing, Blood Tests, Stool Tests, Survey Completion, Endoscopic pancreatic function tests (ePFTs), Secretin
Diagnostic Test · Genetic · Other + 1 more
Lead sponsor
Children's Hospital Medical Center, Cincinnati
Other
Eligibility
5 Years to 21 Years
Enrollment
195 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2027
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Mar 18, 2026 · Synced Oct 31, 2026, 5:15 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Effect of Exendin-(9-39) on Glycemic Control in Subjects With Congenital Hyperinsulinism

NCT00571324
View directory record Official record
Conditions
Congenital Hyperinsulinism
Interventions
Exendin-(9-39), Vehicle
Drug · Other
Lead sponsor
Diva De Leon
Other
Eligibility
7 Years to 60 Years
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2014
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Dec 11, 2017 · Synced Oct 31, 2026, 5:15 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Effects of Prolonged Fasting on Microbiome and HDL

NCT03487679
View directory record Official record
Conditions
Fasting
Interventions
Fasting
Other
Lead sponsor
University of California, Davis
Other
Eligibility
20 Years to 80 Years
Enrollment
21 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018
U.S. locations
1
States / cities
Davis, California
Source: ClinicalTrials.gov public record
Updated Sep 27, 2018 · Synced Oct 31, 2026, 5:15 PM EDT
Recruiting Not applicable Interventional

Healthy Lifestyles for Bipolar Disorder

NCT06188754
View directory record Official record
Conditions
Time Restricted Eating, Diet, Mediterranean
Interventions
Time restricted eating, Mediterranean diet
Behavioral
Lead sponsor
University of California, Berkeley
Other
Eligibility
18 Years to 65 Years
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2029
U.S. locations
1
States / cities
Berkeley, California
Source: ClinicalTrials.gov public record
Updated Aug 4, 2026 · Synced Oct 31, 2026, 5:15 PM EDT
Completed Phase 2 Interventional Results available

Phase 2 Randomized, Double-Blind, Placebo-Controlled, Parallel Group Trial of Linaclotide Administered to Patients With Opioid-Induced Constipation Receiving Chronic Opioid Treatment for Non-Cancer Pain

NCT02270983
View directory record Official record
Conditions
Opioid-Induced Constipation
Interventions
Linaclotide 145 micrograms, Linaclotide 290 micrograms, Placebo
Drug
Lead sponsor
Forest Laboratories
Industry
Eligibility
18 Years and older
Enrollment
254 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
77
States / cities
Anniston, Alabama • Foley, Alabama • Phoenix, Arizona + 67 more
Source: ClinicalTrials.gov public record
Updated Apr 8, 2019 · Synced Oct 31, 2026, 5:15 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Phase 1 TAK-041 First-in-Human Safety, Tolerability, and Pharmacokinetics Study

NCT02748694
View directory record Official record
Conditions
Healthy Volunteers, Schizophrenia
Interventions
TAK-041, TAK-041 Placebo
Drug
Lead sponsor
Neurocrine Biosciences
Industry
Eligibility
18 Years to 55 Years
Enrollment
114 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2019
U.S. locations
1
States / cities
Glendale, California
Source: ClinicalTrials.gov public record
Updated Mar 19, 2021 · Synced Oct 31, 2026, 5:15 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Call-2-Health: Preventing Type II Diabetes

NCT01827826
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
Telephonic intervention to prevent Diabetes Mellitus, Type 2
Behavioral
Lead sponsor
Kaiser Permanente
Other
Eligibility
40 Years to 74 Years
Enrollment
47 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2012
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Oct 13, 2017 · Synced Oct 31, 2026, 5:15 PM EDT
Completed Not applicable Interventional

Feasibility of Fasting & Exercise in Pts With HR+ MBC

NCT04708860
View directory record Official record
Conditions
Breast Cancer, Metastatic Breast Cancer
Interventions
Prolonged Nightly Fasting, Exercise
Behavioral
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years and older · Female only
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Aug 16, 2024 · Synced Oct 31, 2026, 5:15 PM EDT
Completed Not applicable Interventional Results available

89Zr-J591 Anti-Prostate-Specific Membrane Antigen Monoclonal Antibody in Patients With Glioblastoma Multiforme

NCT02410577
View directory record Official record
Conditions
Glioblastoma
Interventions
89Zr-J591, PET/CT Scan, MRI, Blood draw
Drug · Device · Other
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
26 Years to 79 Years
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Mar 19, 2019 · Synced Oct 31, 2026, 5:15 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Sympathetic Activation in Obesity

NCT04946552
View directory record Official record
Conditions
Obesity, Healthy
Interventions
PET Scan, Mixed Meal Test, Muscle sympathetic nerve activity (MSNA), Oral Glucose Tolerance Test, Body Composition, Percent Body Fat & Percent Body Water (Tanita scale), CT Scan, Body Composition, Percent Body Fat & Percent Body Water (DXA Scan)
Diagnostic Test · Dietary Supplement · Other
Lead sponsor
Yale University
Other
Eligibility
18 Years to 45 Years
Enrollment
5 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Feb 16, 2024 · Synced Oct 31, 2026, 5:15 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Food Effect Study to Evaluate the Relative Bioavailability of Nalbuphine Extended-Release Tablets (NAL ER) in Healthy Participants

NCT07487740
View directory record Official record
Conditions
Healthy Participants
Interventions
NAL ER
Drug
Lead sponsor
Trevi Therapeutics
Industry
Eligibility
18 Years to 60 Years
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Aug 21, 2026 · Synced Oct 31, 2026, 5:15 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Study Investigating the Effect of Food and Esomeprazole on the Single Oral Dose Pharmacokinetics of Alectinib (RO5424802) in Healthy Volunteers.

NCT02023125
View directory record Official record
Conditions
Healthy Volunteer
Interventions
Alectinib, Esomeprazole, High Fat and Calorie Meal, Standard Meal
Drug · Other
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years to 55 Years
Enrollment
42 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2014
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Oct 7, 2016 · Synced Oct 31, 2026, 5:15 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

The UnProcessed Pantry Project (UP3)

NCT04241133
View directory record Official record
Conditions
Diet, Healthy, Diet Habit, Disease, Chronic, Health Behavior, Rural Health
Interventions
The UnProcessed Pantry Project (UP3)
Behavioral
Lead sponsor
Montana State University
Other
Eligibility
18 Years and older
Enrollment
78 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020
U.S. locations
1
States / cities
Bozeman, Montana
Source: ClinicalTrials.gov public record
Updated May 2, 2022 · Synced Oct 31, 2026, 5:15 PM EDT
Completed Phase 1 Interventional Results available

First In Human, Phase 1 Study of AG013736 In Patients With Solid Tumors

NCT01469052
View directory record Official record
Conditions
Advanced Solid Tumors
Interventions
AG-013736
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2004
U.S. locations
3
States / cities
San Francisco, California • Houston, Texas • Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Mar 26, 2012 · Synced Oct 31, 2026, 5:15 PM EDT
Recruiting Phase 1 Interventional Accepts healthy volunteers

TREAD: Time Restricted Eating Intervention for Alzheimer's Disease

NCT06548191
View directory record Official record
Conditions
Mild Cognitive Impairment, Alzheimer Disease, Alzheimer's Disease
Interventions
Time-restricted eating
Behavioral
Lead sponsor
University of California, San Diego
Other
Eligibility
60 Years and older
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2027
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated May 26, 2026 · Synced Oct 31, 2026, 5:15 PM EDT